BibTex format
@inproceedings{Mullish:2024:10.1182/blood-2024-204750,
author = {Mullish, BH and Innes, AJ and Ghani, R and Anim-Burton, S and Webber, L and Wheeler, G and Johnson, NA and Roberts, L and Davies, FJ and Marchesi, JR and Pavlu, J},
doi = {10.1182/blood-2024-204750},
pages = {4892.1--4892.1},
publisher = {American Society of Hematology},
title = {Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial},
url = {http://dx.doi.org/10.1182/blood-2024-204750},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - CPAPER
AB - <jats:sec> <jats:title/> <jats:p>Background and significance: Reduced gut microbiome diversity pre-allogeneic hematopoietic cell transplantation (HCT) strongly correlates with poorer survival after the procedure. Most hematologic malignancy patients undergoing HCT have previously received intensive chemotherapy, resulting in prolonged neutropenic episodes and opportunistic infections (increasingly with multidrug-resistant organisms (MDRO)), requiring broad-spectrum antibiotics. The combination of chemotherapy and antimicrobial use has particularly been linked to reduced gut microbiome diversity.</jats:p> <jats:p>Intestinal microbiota transplant (IMT) is a novel treatment approach that can restore this perturbed diversity and has shown promise in a cohort of patients colonized with MDRO in their intestine by reducing post-HCT infection burden and improving overall survival. Given that most patients undergoing HCT will have a disrupted microbiome from prior therapies, we hypothesized that offering IMT prior to initiation of HCT conditioning could improve microbiome diversity during the early stages of HCT, with potential to reduce the frequency of infective complications, and improve outcomes of HCT. Studies using IMT post-HCT have shown variable results, but one distinctive aspect of this study is pre-HCT administration of IMT, aiming to ‘prehabilitate’ the gut prior to the microbiota insults inherent to HCT.</jats:p> <jats:p>Study Design and Methods: The trial is registered (ClinicalTrials.gov ID: NCT 6355583) and recruitment started in 2024.Fifty adult patients planned to receive allogeneic HCT for hematologic malignancies will be recruited into this phase IIa trial, and randomized 1:1 to receive capsulized IMT (10 capsules of EBX-102-02, a next generation, full-spectrum microbiome product derived from pooled screened donor stool; EnteroBiotix L
AU - Mullish,BH
AU - Innes,AJ
AU - Ghani,R
AU - Anim-Burton,S
AU - Webber,L
AU - Wheeler,G
AU - Johnson,NA
AU - Roberts,L
AU - Davies,FJ
AU - Marchesi,JR
AU - Pavlu,J
DO - 10.1182/blood-2024-204750
EP - 1
PB - American Society of Hematology
PY - 2024///
SN - 0006-4971
SP - 4892
TI - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial
UR - http://dx.doi.org/10.1182/blood-2024-204750
UR - https://doi.org/10.1182/blood-2024-204750
ER -